BioStock: Biosergen’s CEO on the latest advancements

As fungal infections continue to be recognized as a growing global health problem, Biosergen is sharpening its focus. The company’s recently published annual report highlights the clinical progress made in 2024 and its priorities in addressing an area with significant unmet medical needs. We contacted CEO Tine Olesen for a comment.  

Read the interview at biostock.se:

https://www.biostock.se/en/2025/05/biosergens-ceo-on-the-latest-advancements/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/